

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number

WO 2014/202646 A1

(43) International Publication Date
24 December 2014 (24.12.2014)

WIPO | PCT

(51) International Patent Classification:

A61K 45/06 (2006.01) *A61P 25/08* (2006.01)
A61K 31/136 (2006.01) *A61P 25/14* (2006.01)
A61K 31/138 (2006.01) *A61P 25/16* (2006.01)

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2014/062786

(22) International Filing Date:

18 June 2014 (18.06.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13382230.4 19 June 2013 (19.06.2013) EP

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(71) Applicant: SOM INNOVATION BIOTECH, S.L. [ES/ES]; C/ Baldiri Reixac, 4, E-08028 Barcelona (ES).

(72) Inventors: GAVALDÀ BATALLA, Núria; Melcior de Palau, 31, 2º-2º, E-08028 Barcelona (ES). INSA BORONAT, Raül; C/ Rosa Sensat, 27, B 1ª, E-08005 Barcelona (ES). REIG BOLAÑO, Núria; Francisco Giner, 13, entr. 1ª, E-08021 Barcelona (ES).

(74) Agent: ZBM PATENTS - ZEA, BARLOCCI & MARK-VARDSEN; Pl. Catalunya, 1 2nd floor, ES-08002 Barcelona (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: THERAPEUTIC AGENTS FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS

(57) Abstract: The present invention relates to the use of (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine having the formula (IA), or a pharmaceutically acceptable salt thereof for the formulation of a pharmaceutical composition, useful for the prophylaxis and/or the treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.

WO 2014/202646 A1

Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders

This invention relates to a second medical indication of known therapeutic agents. Particularly, this invention relates to a therapeutic agent having two aromatic carbocyclic rings connected by a (C₄-C₇)alkyl chain comprising at least one nitrogen or oxygen atom for use in the prophylaxis and/or treatment of hyperkinetic movement disorders.

10 BACKGROUND ART

Movement disorders are a group of central nervous system conditions and/or diseases in which the control of movement is altered with relative preservation of strength, muscle bulk, and mechanical range of motion. They include those diseases which either involve an excess of movement or with a paucity of voluntary and automatic movements. Thus, the movement disorders can be divided into hyperkinesias (excessive movements), dyskinesias (unnatural movements), hypokinesias (paucity of movements), and abnormal involuntary movements.

20 Hyperkinetic movement disorders (also known as hyperkinesia) imply an increase in muscular activity that can result in excessive movements, either normal, or abnormal movements, or a combination of both.

The hyperkinetic movements can be defined as a wide array of movement disorders characterized by excessive repetitive or sporadic involuntary movements. The most frequently hyperkinetic symptoms are, among others, ataxia, athetosis, chorea, dystonia, ballismus, hemifacial spasm, myoclonus, stereotypes, tardive dystonia, tics, and tremors. The movements can be rhythmic, discrete, repeated, and/or random. The specific pathophysiology of these disorders is diverse although many hyperkinetic movements are the result of improper regulation of the basal ganglia-thalamocortical circuitry.

35 Each disorder can feature one or more hyperkinetic movements as prominent symptoms, for example in disorders like Huntington's disease, tardive dyskinesia and Tourette syndrome.

Huntington's disease (HD) is a dominantly inherited neurodegenerative

genetic disorder that affects muscle coordination and leads to cognitive decline and psychiatric problems. HD is due to mutations in the gene encoding for huntingtin, and it is the most common genetic cause of abnormal involuntary writhing movements called chorea, which is why the disease used 5 to be called Huntington's chorea. Thus, the term "Huntington's disease" and "Huntington's chorea" have the same meaning and are used interchangeable. The most prominent early effects in HD are in a part of the basal ganglia called the neostriatum, which is composed of the caudate nucleus and putamen. Symptoms of the disease can vary between individuals, but usually 10 progress predictably. The earliest symptoms are often subtle problems with mood or cognition, followed by a general lack of coordination and an unsteady gait. In advanced stages of the disease, uncoordinated, jerky body movements become more apparent, along with a decline in mental abilities, as well as behavioural and psychiatric problems. Physical abilities are gradually 15 impeded until coordinated movement becomes very difficult, and mental abilities generally decline into dementia. Although the genetic basis of the pathology is well known there is not yet a cure for HD. The pharmacological and non-pharmacological treatments disclosed in the state of the art are focused in minimizing the symptoms of the disease, mainly in relieving the 20 hyperkinetic movements associated to HD.

Tourette syndrome (TS) is a neurologic disorder manifested by motor and vocal or phonic tics usually starting during childhood and often accompanied by some comorbid behavioural problems such as obsessive-compulsive 25 disorder or attention-deficit hyperactivity disorder. Tics are defined as involuntary, sudden, rapid, recurrent, non-rhythmic movement (motor tics) and vocalisations (vocal or phonic tics). The cause of TS is yet unknown, but the disorder appears to be inherited in the majority of patients, as shown by early family studies. Little is known about the exact brain mechanisms associated 30 with tic development and expression, although preliminary evidence from neurochemical and neuroimaging investigations suggests a primary role for dysfunction of the dopaminergic pathways within the cortico-striato-cortico-frontal circuitry. Treatment of TS includes both pharmacotherapy and cognitive behavioural treatment.

35

Tardive dyskinesia (TD) is a disorder characterized by involuntary, repetitive body movements and is the result of treatment with dopamine receptor-

blocking agents. The principal site affected by classic TD is the face, particularly around the mouth, typically called oral-buccal-facial dyskinesia. The limbs and trunk are affected less often than the mouth. The TD syndromes tend to appear late in the course of treatment, hence the term 5 *tardive*. The symptoms can occur when the patient is taking these drugs or within a period of time after stopping the treatment.

The restless legs syndrome (RLS) is characterized by a deep, ill-defined discomfort or dysesthesia in the legs, which arises during prolonged rest, or 10 when the patient is drowsy and trying to fall asleep, especially at night. The most commonly associated medical condition is iron deficiency although there is also evidence to suggest that the disorder in many if not most patients is transmitted as an autosomal dominant trait.

15 Wilson's disease is an inborn error of copper metabolism manifest as hepatic cirrhosis and basal ganglia damage. The condition is due to mutations in the Wilson disease protein (ATP7B) gene and the initial manifestations of the illness are neurologic in about 40% of patients. The pathologic abnormalities in the brain are primarily in the basal ganglia, with cavitary necrosis of the 20 putamen and caudate, associated with neuronal loss, axonal degeneration and astrocytosis. In addition, there is cortical atrophy.

One of the pharmacological symptomatic treatments of the hyperkinetic movement disorders disclosed in the state of the art is based on the 25 administration of an inhibitor of the vesicular monoamine transporter 2 (VMAT2). In the striatum, VMAT2 mainly transports dopamine from cellular cytosol into synaptic vesicles from dopaminergic neurons, protecting it from auto-oxidization in the presence of oxygen radicals. Thus, inhibition of VMAT2 reduces the uptake of dopamine into the synaptic vesicles resulting in an 30 overall reduction in total dopamine.


In particular, tetrabenazine ((SS,RR)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-pyrido[2,1-a]isoquinolin-2-one) is a selective inhibitor of the monoamine transporter VMAT2 which blocks the transport of dopamine to the 35 presynaptic neuronal vesicles, impairing its release to the synaptic cleft. Tetrabenazine is a reversible inhibitor of VMAT2, and the approved drug for the symptomatic treatment of chorea associated to Huntington's disease,

tardive dyskinesia, and Tourette syndrome, as well as for symptoms like hemiballismus.

- Unfortunately, tetrabenazine has a poor and variable bioavailability, being also
- 5 extensively metabolised by first-pass metabolism. Additionally, tetrabenazine has a black-box warning because of an increase in depression and suicidality, as well as the potential to cause Parkinsonism and Neuroleptic Malignant Syndrome.
- 10 Despite all the research efforts invested in the past, the prophylaxis and/or treatment of hyperkinetic movement disorders is far from being satisfactory. Therefore, there is a high unmet need for a safe and effective treatment for those disorders.

15 SUMMARY OF THE INVENTION


- Inventors have surprisingly found that compounds of formula (I) allow the prevention or the amelioration of hyperkinetic movement disorders. As it is shown in the examples below, the compounds of the invention have been
- 20 identified as VMAT2 inhibitors, exhibiting similar VMAT2 inhibition values compared with tetrabenazine, the marketed active ingredient for the treatment of the above mentioned disorders. Thus, the compounds of formula (I) have an effective activity in the prophylaxis and/or treatment of hyperkinetic movement disorders.
- 25 The embodiments of the invention can be applied to all symptoms related to unwanted and excess movement associated to hyperkinesias. The present invention also engages from initial to advanced stages of the evolution of hyperkinesias.
- 30 Accordingly, the present invention relates to compounds of formula (I) or their pharmaceutically acceptable salts



- for use in the prophylaxis and/or treatment of some hyperkinetic movement disorders; wherein: R₁ is selected from the group consisting of H, CH₃, and 10 CF₃; R₂ is selected from the group consisting of H, OH, and CH₃; R₃ is H or -CH₂CH₂Cl; R₄ is H or CH₃; Ar is selected from the group consisting of 1-naphtyl, phenyl, and 3,4-dimethoxyphenyl; X is CH₂ or O; and m, and n are integers selected from 0 and 1; with the proviso that: R₁ is CH₃, R₂ is OH, R₃ is H, R₄ is H, Ar is 3,4-dimethoxyphenyl, X is O, m is 1, and n is 1; or R₁ is CF₃, 15 R₂ is H, R₃ is H, R₄ is CH₃, Ar is 1-naphtyl, X is CH₂, m is 0, and n is 0; or R₁ is H, R₂ is CH₃, R₃ is -CH₂CH₂Cl, R₄ is H, Ar is phenyl, X is O, m is 0, and n is 0.

The compounds of formula (I) are: bevantolol, cinacalcet, and phenoxybenzamine.


- 20 Bevantolol is the name commonly used for (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine having CAS RN 59170-23-9 of formula (IA)



- 30 It is a beta-1 adrenoreceptor antagonist that has been shown to also have both agonist and antagonist effects on alpha adrenoreceptor. It is used for the treatment of angina pectoris and hypertension.

- 35 Cinacalcet is the name commonly used for (R)-N-[1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine) having CAS RN 226256-56-0 of formula (IB).

5




(IB)

10 It is an active ingredient that acts as a calcimimetic agent by allosteric activation of the calcium-sensing receptor expressed in the surface of the chief cell of the parathyroid gland. It has been safely administered to humans for the treatment of secondary hyperparathyroidism and for the parathyroid carcinoma.

15

WO2012117073 discloses a combined therapy for the treatment of neurological disorders which comprises a first active ingredient selected from a first list and at least a second active ingredient selected from a second list, wherein the second list includes among others cinacalcet. In particular, it is 20 only disclosed the effect on the cognitive performance on Alzheimer's disease animal models.

25 Phenoxybenzamine is the name commonly used for (RS)-N-benzyl-N-(2-chloroethyl)-1-phenoxy-propan-2-amine having CAS RN 59-96-1 of formula (IC)



30


(IC)

It is a non-selective, irreversible alpha adrenoreceptor antagonist that has been indicated to control episodes of hypertension and sweating in the treatment of pheochromocytoma.

35 In particular, the present invention relates to a compound of formula (IA) or a

pharmaceutically acceptable salt thereof

5



for use in the prophylaxis and/or treatment of a hyperkinetic movement

disorder associated with Huntington's disease, Wilson's disease, Tourette

10 syndrome, restless leg syndrome, and tardive dyskinesia.

Consequently, none of the compounds of formula (I) have already been disclosed or suggested for the prophylaxis and/or treatment of hyperkinetic movement disorders.

DETAILED DESCRIPTION OF PARTICULAR EMBODIMENTS


15

As mentioned above, the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in the prophylaxis and/or treatment of hyperkinetic movement disorders. This aspect could be formulated as the use of a compound of formula (I) or a pharmaceutically

20 acceptable salt thereof for the preparation of a medicament for the prophylactic and/or therapeutic treatment of hyperkinetic movement disorders in a mammal, including a human. This aspect could also be formulated as a method for the treatment and/or prophylaxis of a mammal, including a human, suffering from or being susceptible of suffering from hyperkinetic movement

25 disorders, the method comprising the administration to said patient of a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, together with pharmaceutically acceptable excipients or carriers.

30 In a particular embodiment, a compound of formula (IA) or a pharmaceutically acceptable salt thereof



5 (IA)

for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, tardive dyskinesia, Wilson's disease, Tourette syndrome, and restless leg syndrome.

10

In an embodiment, a compound of formula (IA) or a pharmaceutically acceptable salt thereof for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, and restless leg syndrome.

15

In an embodiment of the invention, the compounds of formula (I) or their pharmaceutically acceptable salt thereof can be used in the treatment of hyperkinetic movement disorders. In a particular embodiment, the compound of formula (IA) or their pharmaceutically acceptable salt thereof, for use in the treatment of the hyperkinetic movement disorder associated with Huntington's disease, tardive dyskinesia, Wilson's disease, Tourette syndrome, and restless leg syndrome. In an embodiment, for use in the treatment of the hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, and restless leg syndrome.

20

Any pharmaceutically acceptable salt of a compound of formula (I) can be used for the purposes of the invention. The expression "pharmaceutically acceptable salt" refers to salts prepared from pharmaceutically acceptable non-toxic acids which are, within the scope of medical judgement, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

25

Some compounds of the invention can have chiral centres that can give rise to various stereoisomers. As used herein, the term "stereoisomer" refers to all isomers of individual compounds that differ only in the orientation of their atoms in space. The term stereoisomer includes mirror image isomers

- (enantiomers), and mixtures of mirror image isomers (racemates, racemic mixtures). The present invention relates to each of these stereoisomers and also mixtures thereof. Enantiomers can be separated by conventional techniques such as chromatography or fractional crystallization. Optical isomers can be resolved by conventional techniques of optical resolution to give optically pure isomers. This resolution can be carried out on any chiral synthetic intermediates or on compounds of the invention. Optically pure isomers can also be individually obtained using enantiospecific synthesis.
- 5
- 10 The expression "pharmaceutically acceptable excipients or carriers" refers to pharmaceutically acceptable materials, compositions or vehicles. Each component must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the pharmaceutical composition. It must also be suitable for use in contact with the tissue or organ of humans
- 15 and animals without excessive toxicity, irritation, allergic response, immunogenicity or other problems or complications commensurate with a reasonable benefit/risk ratio.
- 20 In a preferred embodiment, the compound for use of the present invention is that wherein R₁ is CH₃, R₂ is OH, R₃ is H, R₄ is H, Ar is 3,4-dimethoxyphenyl, X is O, m is 1, and n is 1. This compound is the known compound bevantolol of formula (IA).
- 25 In another preferred embodiment, the compound for use of the present invention is that wherein R₁ is CF₃, R₂ is OH, R₃ is H, R₄ is H, Ar is 3,4-dimethoxyphenyl, X is O, m is 1, and n is 1. This compound is the known compound cinacalcet of formula (IB).
- 30 In another preferred embodiment, the compound for use of the present invention is that wherein R₁ is H, R₂ is CH₃, R₃ is -CH₂CH₂Cl, R₄ is H, Ar is phenyl, X is O, m is 0, and n is 0. This compound is the known compound phenoxybenzamine of formula (IC).
- 35 The compounds of the invention are used in the prophylaxis and/or treatment of hyperkinetic movement disorders. Examples of hyperkinetic movements include abdominal dyskinesias, akathisic movements, asynergia, ataxia, athetosis, ballism, chorea, dysmetria, dystonia, hemifacial spasm,

- hyperekplexia, hypnogenic dyskinesias, jumpy stumps, moving toes and/or fingers, myoclonus, myokymia, myorhythmia, paroxysmal dyskinesias, tics, and tremor. In an embodiment of the invention, the hyperkinetic movement disorders are selected from the group consisting of chorea, dystonia, 5 myoclonus, stereotypy, tics, ballism and tremors. In a preferred embodiment, the hyperkinetic movement disorder is selected from tics, ballism, dystonia and chorea.

- In a preferred embodiment, the hyperkinetic movement disorder is chorea.
- 10 The term chorea as used herein refers to a hyperkinetic movement disorder that consists of involuntary, continual, abrupt, rapid, brief, unsustained, irregular movements that flow randomly from one body part to another. Chorea may be a manifestation of a primary neurologic genetic disorder, such as Huntington's disease, or it may occur as a neurologic complication of other 15 disorders such as systemic disorders, toxic disorders, and/or a pharmacological treatment such as the treatment with dopamine receptors antagonists, causing, for example, tardive chorea and withdrawal emergent syndrome.
- 20 In another preferred embodiment, the hyperkinetic movement disorder is ballism. It refers to a rare movement disorder that consists of flailing, ballistic, and undesired movements of the limbs. The involuntary movement usually affects only one side of the body; the term hemiballism is used to describe unilateral ballism. Damage to the subthalamic nucleus and the pallido- 25 subthalamic pathways are the main causes associated with ballism.
- In another preferred embodiment the hyperkinetic movement disorder is tic. It refers to relatively brief, abrupt and intermittent movement (motor tics) or sounds (vocal or phonic tics). They vary in frequency and intensity and often 30 change distribution. Increased activity in the right caudate nucleus, right frontal cortex and other cortical areas of the brain has been related to the appearance of tics.
- In another preferred embodiment the hyperkinetic movement disorder is 35 dystonia. It refers to involuntary movements and extended muscle contractions. The dystonic patient has twisting body movements, tremor and unusual or awkward postures. For some patients the whole body may be

involved in the movements, while for others only certain parts of the body are affected. Dystonia can be classified by age of onset, by body parts(s) affected and by etiology (primary or secondary). Decreased neurotransmitter production in the basal ganglia is most likely associated with primary dystonia 5 symptoms. However, there are also a number of dystonias that have a genetic origin.

The hyperkinetic movements as mentioned above can be associated with several diseases or disorders. Examples of diseases that feature one or more 10 hyperkinetic movements include, Huntington's disease, Huntington's disease-like diseases (HDL1, HDL2 and HDL3), Sydenham chorea, benign hereditary chorea, neuroacanthocytosis, neurodegeneration with brain iron accumulation (NBIA), athetosis, Wilson's disease, Tourette syndrome, restless leg syndrome, tardive dyskinesia, Friedreich ataxia, spinocerebellar ataxia, 15 multiple system atrophy, dentatorubral-pallidoluysian atrophy, ataxia with oculomotor apraxia (types 1 and 2), ataxia telangiectasia, focal dystonias, idiopathic dystonias such as Oppenheim dystonia and torticollis, dystonia-plus syndromes, secondary dystonias, Duchenne muscular dystrophy, Down syndrome, Parkinson's disease, and progressive supranuclear palsy.

20 In an embodiment of the invention, suitable diseases that feature one or more of hyperkinetic movements for the present invention are selected from the group consisting of Huntington's disease, Wilson's disease, Tourette syndrome, tardive dyskinesia and restless leg syndrome. In an embodiment, 25 the hyperkinetic movements for the present invention are selected from the group consisting of Huntington's disease, Wilson's disease, Tourette syndrome and restless leg syndrome. In a preferred embodiment, the disease is selected from Huntington's disease, Tourette syndrome, and tardive dyskinesia.

30 In a preferred embodiment, the compound of formula (I) for use in the prophylaxis and/or treatment of chorea associated to Huntington's disease, Tourette syndrome, and tardive dyskinesia. Particularly, the compound of formula (I) for use in the prophylaxis and/or treatment of chorea associated to 35 Huntington's disease. In a particular embodiment, the compound of formula (IA) for use in the prophylaxis and/or treatment of chorea associated to Huntington's disease, Tourette syndrome, and tardive dyskinesia. Particularly,

in the prophylaxis and/or treatment of chorea associated to Huntington's disease.

5 In another preferred embodiment, the compound of formula (I) for use in the prophylaxis and/or treatment of tics associated to Tourette syndrome and tardive dyskinesia.

Effective quantities of a compound of formula (I), particularly the compound of formula (IA) or pharmaceutically acceptable salts thereof are preferably 10 administered to a patient in need of such treatment according to usual routes of administration and formulated in usual pharmaceutical compositions, comprising an effective amount of the active ingredient and a suitable pharmaceutically acceptable carrier, and dosage forms according to methods known in the art.

15 The expression "therapeutically effective amount" as used herein, refers to the amount of the active ingredient that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disease which is addressed. The particular dose of 20 compound administered according to this invention will be determined by the particular circumstances surrounding the case, including the compound administered, the route of administration, the particular condition being treated, and similar considerations. In particular, the term "therapeutically effective amount of a compound of formula (I)" as used herein, refers to the 25 amount of the compound of formula (I) that is sufficient to prevent or alleviate to some extent one or more of the hyperkinetic movement. Particularly, the amount of the compound of formula (I) that is sufficient to prevent or alleviate to some extent one or more of the hyperkinetic movement associated to HD. In particular, the term "therapeutically effective amount of a compound of 30 formula (IA)" as used herein refers to the amount of the compound of formula (IA) that is sufficient to prevent or alleviate to some extent one or more of the hyperkinetic movement associated with Huntington's disease, Wilson's disease, Tourette syndrome, tardive dyskinesia and restless leg syndrome; Particularly, Huntington's disease, Wilson's disease, Tourette syndrome, and 35 restless leg syndrome. In an embodiment, the amount of the compound of formula (I), particularly (IA) that is sufficient to prevent or alleviate to some extent one or more of the hyperkinetic movement associated to Huntington's

disease, Tourette syndrome and tardive dyskinesia.

The individual dosage as well as the daily dosage varies depending upon the type and severity of the hyperkinetic movement to be treated, and the specific 5 patient's response to the medication. Therefore, the exact individual dosage will be determined according to standard medical principles under the direction of a physician.

10 The effective daily dose of a compound of formula (I) for use in the treatment of hyperkinetic movement disorders is comprised from 1 to 10000 mg/day. In a particular embodiment, when the compound of formula (I) is the compound of formula (IA), the effective daily dose for use in the treatment of hyperkinetic movement disorders is comprised from 1 to 6000 mg/day; preferably from 1 to 3000 mg/day; more preferably from 1 to 600 mg/day. In another particular 15 embodiment, when the compound of formula (I) is the compound of formula (IB), the effective daily dose for use in the treatment of hyperkinetic movement disorders is comprised from 1 to 4000 mg/day; preferably from 1 to 400 mg/day. In another particular embodiment, when the compound of formula (I) is the compound of formula (IC), the effective daily dose for use in the 20 treatment of hyperkinetic movement disorders is comprised from 1 to 2000 mg/day; preferably from 1 to 200 mg/day.

25 The compound of formula (I) or a pharmaceutically acceptable salt thereof can be used either alone or in combination therapy with another compound of formula (I) or with other therapeutic agents. In a particular embodiment, the compound of formula (IA) or a pharmaceutically acceptable salt thereof can be used either alone or in combination therapy with a compound of formula (IB), a compound of formula (IC) or with other therapeutic agents.

30 In an embodiment of the invention, the compound of formula (I) for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder, wherein said prophylaxis or treatment comprises administering as a unique active ingredient the compound of formula (I). In a particular embodiment, the compound of formula (IA) for use in the prophylaxis and/or treatment of a 35 hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, tardive dyskinesia and restless leg syndrome, wherein said prophylaxis or treatment comprises administering as

a unique active ingredient the compound of formula (IA); particularly Huntington's disease, Wilson's disease, Tourette syndrome, and restless leg syndrome.

- 5 In another embodiment of the invention, the compound of formula (I) for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder, wherein said prophylaxis or treatment comprises administering the compound of formula (I) in combination therapy with an additional therapeutic agent selected from the group consisting of another compound of formula (I), a
- 10 neuroleptic agent, an anti-glutamatergic agent, a dopamine depleting agent, an acetyl cholinesterase inhibitor, and mixture thereof. In a preferred embodiment, the additional therapeutic agent is selected from the group consisting of another compound of formula (I), amantadine, riluzole, tetrabenazine, reserpine, and donepezil; preferably, the additional therapeutic
- 15 agent is tetrabenazine.

In a particular embodiment, the compound of formula (IA) for use in the prophylaxis or treatment comprises administering the compound of formula (IA) in combination therapy with an additional therapeutic agent selected from


20 the group consisting of a compound of formula (IB), a compound of formula (IC), a neuroleptic agent, an anti-glutamatergic agent, a dopamine depleting agent, an acetyl cholinesterase inhibitor, and mixture thereof;

wherein:

25

the compound of formula (IB) is


30



(IB)

and the compound of formula (IC) is

35



5

(IC)

As will be apparent to the skilled in the art, the combination of the invention comprising a compound of formula (I) with an additional therapeutic agent is effective not only when the active ingredients are used in a single composition, but also when used in two different compositions, either administered simultaneously, sequentially or separately after a certain period of time. Furthermore, the skilled in the art will understand that the compound of formula (I), particularly compound of formula (IA), can be prescribed to be used together with the other active ingredient in a combination therapy in order to prevent and/or treat a hyperkinetic movement disorder.

In a particular embodiment, the combination therapy comprises administering to a subject simultaneously, sequentially or separately the compound of formula (I) and the additional therapeutic agent. Alternatively, the combination therapy comprises administering to a subject the compound of formula (I) and the additional therapeutic agent in a single composition.

In a particular embodiment, the combination therapy comprises administering to a subject simultaneously, sequentially or separately the compound of formula (IA) and the additional therapeutic agent. Alternatively, the combination therapy comprises administering to a subject the compound of formula (IA) and the additional therapeutic agent in a single composition.

The invention also refers to a combination of a compound of formula (I) and an additional therapeutic agent as defined above, for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder. In a particular embodiment, the invention also refers to a combination of a compound of formula (IA) and an additional therapeutic agent as defined above, for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, tardive dyskinesia and restless leg syndrome; particularly in the prophylaxis

and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, and restless leg syndrome.

- 5 In an embodiment of the invention the compound of formula (I) or pharmaceutically acceptable salts thereof can be conveniently administered to a patient. Thus, the compound for use of the present invention can be in form of a pharmaceutical composition comprising an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in
10 combination with pharmaceutically acceptable excipients or carriers. This aspect can also be formulated as a pharmaceutical composition comprising an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients or carriers for use in the prophylaxis and/or treatment of the
15 hyperkinetic movement disorders.

In a particular embodiment of the invention, the compound of formula (IA) or pharmaceutically acceptable salts thereof can be conveniently administered to a patient. Thus, the compound for use of the present invention can be in form of a pharmaceutical composition comprising an effective amount of a compound of formula (IA) or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients or carriers. This aspect can also be formulated as a pharmaceutical composition comprising an effective amount of a compound of formula (IA) or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients or carriers for use in the prophylaxis and/or treatment of the hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Tourette syndrome, tardive dyskinesia and restless leg syndrome; particularly in the prophylaxis and/or treatment of a hyperkinetic
25 movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, and restless leg syndrome.
30

In an embodiment of the invention, the compound for use is in form of oral unit dosage form. In another embodiment of the invention, the compound for use is in form of intraoral unit dosage form including sublingual and buccal. Preferred pharmaceutical compositions are solid pharmaceutical compositions which rapidly disintegrate in the mouth of a subject, upon insertion into the buccal
35

- pouch or upon placement under the tongue. Examples of oral dosage forms suitable for the present invention include solid dosage forms like tablets, powders, capsules, sachets, as well as liquid syrups, suspensions and elixirs. Pharmaceutically acceptable carriers and excipients suitable for use in the
- 5 oral formulations disclosed herein include, but are not limited to, diluents such as fillers and bulking agents, binders, lubricants, anti-caking agents, disintegrants, sweeteners, buffering agents, preservatives, solubility enhancers, isotonic agents, suspending and dispersing agents, wetting or emulsifying agents, flavours and aromas, thickening agents, and vehicles.
- 10 In another embodiment, the compound for use of the present invention is in form of inhalation unit dosage form, which is inhaled through the mouth or the nose administered via an aerosol or a dry powder inhaler. Examples of inhalation dosage forms suitable for the present invention include, among
- 15 others, solutions, suspensions, and powders. Solutions and suspensions can be administered by atomizers, nebulizers, and vaporizes aerosol devices; and powders can be administered by insufflators or puffers. Pharmaceutically acceptable carriers and excipients suitable for use in the inhalation formulations disclosed herein include, but are not limited to, preservatives,
- 20 buffer salts, viscosity modifying agents, suspending agents, pH-adjusting agents, tonicity adjusting agent, solvent, co-solvent, surfactant and flavours.
- The pressurized dispersers of the invention can be in form of a unit dose, bi-dose or multi-dose devices. The pressurized dispersers defined further
- 25 comprise at least one propellant agent. The propellant is the agent that supplies the necessary pressure within the aerosol, nebulizer or insufflator system to expel the material from the container. Propellants are commonly classified as liquefied or compressed gases having vapour pressures generally exceeding atmospheric pressure. Examples of suitable propellants
- 30 for the present invention includes hydrocarbons, especially halogenated derivatives of methane, ethane, and propane, low molecular weight hydrocarbons such as the butanes and pentanes, and compressed gases such as carbon dioxide, nitrogen, and nitrous oxide. Mixtures of propellants are frequently used to obtain desirable pressure, delivery, and spray
- 35 characteristics.

In another embodiment, the compound for use of the present invention is in form of topical unit dosage form to be applied to the skin or mucous membranes of a patient to be treated. Examples of topical dosage forms suitable for the present invention include transdermal patches, transdermal 5 plasters, solutions, aerosols and non-aerosol sprays, creams, powders, lotions, gels, ointments, pastes, emulsions, pens or sticks. Pharmaceutically acceptable carriers and excipients suitable for use in the topical formulations disclosed herein include, but are not limited to, an emollient, a thickener, a humectant, a pH-regulating agent, an antioxidant, a preservative agent, 10 solubility enhancers, isotonic agents, suspending and dispersing agents, wetting or emulsifying agents, flavours and aromas, thickening agents, and vehicles or their mixtures.

Throughout the description and claims the term "comprise" and variations of 15 the word, are not intended to exclude other technical features, additives, components, or steps. The term includes the expression "consist of" and variations thereof. Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following 20 examples are provided by way of illustration, and they are not intended to be limiting of the present invention. Furthermore, the present invention covers all possible combinations of particular and preferred embodiments described herein.

25 **EXAMPLES**

Example 1. VMAT2 Assay

VMAT2 Functional Assay determines the interaction between the compounds 30 of the present invention and the VMAT2 present in isolated cerebral cortical vesicles. The VMAT2 assay used in the present invention is the assay disclosed by Sandoval et al in 2002 (Sandoval et al; "Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors". Journal of Neuroscience. 2002, Vol. 22, pp. 8705-8710).

35

A. Materials

Transporter Source: Rat cortical vesicles

Buffers: 100 mM potassium tartrate, 1.7 mM ascorbic acid, 0.05 mM EGTA, 0.1 mM EDTA, 2 mM Magnesium-ATP and 25 mM HEPES.

5

RadioLigand: Monoamine: [3H]-Dopamine
Final ligand concentration: 30 nM

KT (transport constant kinetic parameter of dopamine): 140 nM

10 Vmax (transport rate): 1800 fmol/mg tissue/min

B. Samples

Positive reference-control: Reserpine
15 Concentration: 10 µM

Comparative sample: Tetrabenazine

Test Samples: (IA) Bevantolol
(IB) Cinacalcet
(IC) Phenoxybenzamine

20 C. Method

(1) Rat cortical vesicles were purified using differential centrifugation, and the vesicles obtained were diluted in the assay buffer and pre-incubated with the positive-reference-control, the comparative sample or a compound of the 25 invention for 30 minutes at room temperature.

(2) Uptake begins with the addition of [3H]-dopamine and the mixture is allowed to incubate for 15 minutes at room temperature.

30 (3) After that time, the reaction was stopped by vacuum filtration, and the amount of radioactivity of the radiolabeled [3H]-dopamine trapped onto the filters was determined.

35 (4) The radioactivity of the [3H]-dopamine trapped was determined using liquid scintillation spectrophotometry (Beckman and Perkin Elmer). The amount of radioactivity obtained with the comparative sample or a compound of the invention was compared with the amount of radioactivity obtained with the positive-reference control (reserpine).

D. Results

The half maximal inhibitory concentration (IC₅₀) of the comparative sample and compounds of the invention was determined by measuring the concentration of competing ligand which displaced 50% of the specific binding 5 of the [³H]-dopamine. The IC₅₀ value is converted to an absolute inhibition constant K_i using the Cheng-Prusoff equation. Two separate independent experiments were performed.

The IC₅₀ values were summarized in Table 1:

10

Table 1

COMPOUND	IC ₅₀ (nM)	
	Experiment 1	Experiment 2
Comparative Sample (tetrabenazine)	10.5	36.7
Bevantolol (IA)	42.8	63.0
Cinacalcet (IB)	44.6	-
Phenoxybenzamine (IC)	58.1	-

The IC₅₀ values on Table 1 show that the compounds of the invention inhibit 15 VMAT2 in the same order of magnitude than the comparative sample (tetrabenazine). The above-mentioned values of IC₅₀ in the VMAT2 inhibition assay are good indicators of the efficacy of the treatment of hyperkinetic movement disorders by the compounds of the present invention.

20


REFERENCES CITED IN THE APPLICATION

1. WO2012117073
2. Sandoval et al; "Methylphenidate redistributes vesicular monoamine 25 transporter-2: role of dopamine receptors". *Journal of Neuroscience*. 2002, Vol. 22, pp. 8705-8710.

CLAIMS

1. A compound of formula (IA) or a pharmaceutically acceptable salt thereof

5




10

for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.

15 2. The compound for use according to claim 1, for use in the treatment of the hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome and tardive dyskinesia.

20 3. A compound of formula (IA) or a pharmaceutically acceptable salt thereof



25

for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome and restless leg syndrome.

30


4. The compound for use according to any of the claims 1-3, wherein said prophylaxis or treatment comprises administering as a unique active ingredient the compound of formula (IA).

35 5. The compound for use according to any of the claims 1-4, wherein said prophylaxis or treatment comprises administering the compound of formula (IA) in combination therapy with an additional therapeutic agent selected from

the group consisting of a compound of formula (IB), a compound of formula (IC), a neuroleptic agent, an anti-glutamatergic agent, a dopamine depleting agent, an acetyl cholinesterase inhibitor, and mixture thereof;


5 wherein:

the compound of formula (IB) is



(IB)

and the compound of formula (IC) is



(IC) C

20

6. The compound for use according to claim 5, wherein the combination therapy comprises administering to a subject simultaneously, sequentially or separately the compound of formula (IA) and the additional therapeutic agent.

25 7. The compound for use according to any of the claims 5 or 6, wherein the additional therapeutic agent is selected from the group consisting of a compound of formula (IB), a compound of formula (IC), amantadine, riluzole, tetrabenazine, reserpine, and donepezil.

30 8. A combination of a compound of formula (IA) and an additional therapeutic agent as defined in any of the claims 5-7, for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.

35

9. A combination of a compound of formula (IA) and an additional therapeutic agent as defined in any of the claims 5-8, for use in the prophylaxis and/or

treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, and restless leg syndrome.

10. The compound for use according to any of the claims 1-9, wherein the hyperkinetic movement disorder is selected from the group consisting of abdominal dyskinesias, akathisic movements, asynergia, ataxia, athetosis, ballism, chorea, dysmetria, dystonia, hemifacial spasm, hyperekplexia, hypnogenic dyskinesias, jumpy stumps, moving toes and/or fingers, myoclonus, myokymia, myorhythmia, paroxysmal dyskinesias, tics, and tremors.
- 15 11. The compound for use according to any of the claims 1-10, wherein the hyperkinetic movement disorder is chorea associated to Huntington's disease, Tourette syndrome, and tardive dyskinesia.
- 20 12. The compound for use according to any of the claims 1-11, wherein the hyperkinetic movement disorder is chorea associated to Huntington's disease.
- 25 13. The compound for use according to any of the claims 1-10, wherein the hyperkinetic movement disorder is tics associated to Tourette syndrome and tardive dyskinesia.
- 30 14. The compound for use according to any of the claims 1-10, wherein the hyperkinetic movement disorder is ballism.
- 35 15. The compound for use according to any of the claims 1-10, wherein the hyperkinetic movement disorder is dystonia.
16. The compound for use according to any of the claims 1-15 as an ingredient of a pharmaceutical composition comprising an effective amount of the compound of formula (IA) or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients or carriers.
17. The compound for use according to claim 16, wherein the pharmaceutical composition is an oral unit dosage form, intraoral unit dosage form, inhalation dosage form, and topical unit dosage form.

18. The combination for use according to any of the claims 8-9, wherein the hyperkinetic movement disorder is chorea associated to Huntington's disease, Tourette syndrome, and tardive dyskinesia.
- 5 19. The combination for use according to any of the claims 8-9, wherein the hyperkinetic movement disorder is chorea associated to Huntington's disease.
- 10 20. The combination for use according to any of the claims 8-9 as an ingredient of a pharmaceutical composition comprising an effective amount of the compound of formula (IA) or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients or carriers.
- 15 21. The combination for use according to claim 20, wherein the pharmaceutical composition is an oral unit dosage form, intraoral unit dosage form, inhalation dosage form, and topical unit dosage form.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2014/062786

A. CLASSIFICATION OF SUBJECT MATTER	INV.	A61K45/06	A61K31/136	A61K31/138	A61P25/08	A61P25/14
		A61P25/16				

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 8 183 415 B2 (THIEL OLIVER [US] ET AL) 22 May 2012 (2012-05-22) column 32, lines 44, 46, 48-49, 52 -----	5-7,9-16
X	US 2010/203168 A1 (ZAMOYSKI MARK JOHN [US]) 12 August 2010 (2010-08-12) claims 1-4 -----	5-7,9-16
Y	WO 2012/117076 A2 (PHARNEXT [FR]; COHEN DANIEL [FR]; CHUMAKOV ILYA [FR]; NABIROCHKIN SERG) 7 September 2012 (2012-09-07) claims 2-3, 6-7 page 37, lines 15-16, 25-30 figure 6 ----- -/-	5-7,9-16

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

8 August 2014

19/08/2014

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Lemarchand, Aude

INTERNATIONAL SEARCH REPORT

International application No PCT/EP2014/062786

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	WO 2013/127918 A1 (PHARNEXT [FR]) 6 September 2013 (2013-09-06) claims 3,5,6 -----	5-7,9-16
X	DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 May 1984 (1984-05-12), LANGLAIS, P. J. ET AL: "Effects of neuropharmacologic agents on a chemically induced hyperkinetic animal model", XP002715363, retrieved from STN Database accession no. 1979:145816 abstract -----	5-7,9-16
Y	MASAKAZU NISHIMURA ET AL: "Involvement of adrenergic and serotonergic nervous mechanisms in allethrin-induced tremors in mice.", THE JOURNAL OF TOXICOLOGICAL SCIENCES, vol. 9, no. 2, 1 May 1984 (1984-05-01), pages 131-142, XP055085032, ISSN: 0388-1350, DOI: 10.2131/jts.9.131 the whole document -----	5-7,9-16
Y	DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1983, MATSUI, KYOKO ET AL: "Relation of the ataxia in Rolling mouse Nagoya to norepinephrine system", XP002715364, retrieved from STN Database accession no. 1983:137876 abstract -----	5-7,9-16
Y	FISCHER W: "[Pharmacologic modulation of central noradrenergic mechanisms and the effect of selected substances on chemically induced seizures: maximal pentylenetetrazole-seizure test (mice)].", DIE PHARMAZIE FEB 1991, vol. 46, no. 2, February 1991 (1991-02), pages 151-152, XP001526367, ISSN: 0031-7144 page 151, right-hand column, last paragraph ----- -/-	5-7,9-16

INTERNATIONAL SEARCH REPORT

International application No PCT/EP2014/062786

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LOFDAHL C G ET AL: "Selectivity of bevantolol hydrochloride, a [beta]1-adrenoceptor antagonist, in asthmatic patients", PHARMACOTHERAPY 1984 US, vol. 4, no. 4, 1984, pages 205-210, XP002715365, ISSN: 0277-0008 abstract page 208, last paragraph - page 209, paragraph first -----	1-21
X	HIRATE K ET AL: "GENERAL PHARMACOLOGICAL STUDIES OF BEVANTOLOL HYDROCHLORIDE A SELECTIVE BETA-1-ADRENOCEPTOR BLOCKING DRUG", OYO YAKURI, vol. 44, no. 2, 1992, pages 167-187, XP009173728, ISSN: 0300-8533 abstract -----	1-21
Y	ZHENG G ET AL: "Vesicular monoamine transporter 2: Role as a novel target for drug development", AAPS JOURNAL 20061110 US, vol. 8, no. 4, 10 November 2006 (2006-11-10), XP055085078, ISSN: 1550-7416 page E687; example 40 -----	1-21
Y	ZHENG FANG ET AL: "Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 15, 1 January 2007 (2007-01-01), pages 2975-2992, XP002515369, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2007.02.013 [retrieved on 2007-02-11] example T69; table 7 ----- -/-	1-21

INTERNATIONAL SEARCH REPORT

International application No PCT/EP2014/062786

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZHANGYU YAO ET AL: "Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 46, no. 5, 17 February 2011 (2011-02-17), pages 1841-1848, XP028370954, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2011.02.046 [retrieved on 2011-02-23] page 1841, lines 1-2, last paragraph sentence bridging the two columns; page 1841, left-hand column - right-hand column -----	1-21
A	JANKOVIC ET AL: "Treatment of hyperkinetic movement disorders", LANCET NEUROLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 8, no. 9, 1 September 2009 (2009-09-01), pages 844-856, XP026448543, ISSN: 1474-4422 [retrieved on 2009-08-10] the whole document -----	1-21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2014/062786

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 8183415	B2	22-05-2012	AU	2008269181 A1	31-12-2008
			CA	2691196 A1	31-12-2008
			EP	2170805 A2	07-04-2010
			JP	5358566 B2	04-12-2013
			JP	2010530428 A	09-09-2010
			US	2009137837 A1	28-05-2009
			US	2011281954 A1	17-11-2011
			WO	2009002427 A2	31-12-2008
<hr style="border-top: 1px dashed black;"/>					
US 2010203168	A1	12-08-2010	US	2010203168 A1	12-08-2010
			US	2012214876 A1	23-08-2012
			US	2013058946 A1	07-03-2013
<hr style="border-top: 1px dashed black;"/>					
WO 2012117076	A2	07-09-2012	AU	2012222351 A1	29-08-2013
			CA	2828765 A1	07-09-2012
			CN	103596562 A	19-02-2014
			DK	2560631 T3	10-02-2014
			EA	201300974 A1	30-01-2014
			EP	2560631 A2	27-02-2013
			EP	2680835 A2	08-01-2014
			EP	2727588 A1	07-05-2014
			ES	2450074 T3	21-03-2014
			HK	1182615 A1	11-07-2014
			HR	P20140131 T1	09-05-2014
			JP	2014510069 A	24-04-2014
			KR	20140038378 A	28-03-2014
			PT	2560631 E	24-02-2014
			SG	192968 A1	30-09-2013
			SI	2560631 T1	30-06-2014
			SM	T201400029 B	07-07-2014
			US	2013085122 A1	04-04-2013
			US	2013090307 A1	11-04-2013
			US	2014080873 A1	20-03-2014
			WO	2012117075 A2	07-09-2012
			WO	2012117076 A2	07-09-2012
<hr style="border-top: 1px dashed black;"/>					
WO 2013127918	A1	06-09-2013	EP	2705842 A1	12-03-2014
			WO	2013127918 A1	06-09-2013
			WO	2014037416 A2	13-03-2014

摘要

本发明涉及具有式(Ia)的(RS)-[2-(3,4-二甲氧基苯基)乙基][2-羟基-3-(3-甲基苯氧基)丙基]胺或其药用盐用于配制药物组合物的用途，其可用于预防和/或治疗与亨廷顿病、威尔逊病、图雷特综合征、下肢不宁综合征和迟发性运动障碍相关的多动性运动障碍。